

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 September 2024 (26.09.2024)



(10) International Publication Number
WO 2024/196788 A1

(51) International Patent Classification:

A61P 25/00 (2006.01) C07D 401/14 (2006.01)
A61P 29/00 (2006.01) C07D 403/04 (2006.01)
A61P 35/00 (2006.01) A61K 31/55 (2006.01)
C07D 401/04 (2006.01) A61K 31/435 (2006.01)

(21) International Application Number:

PCT/US2024/020220

(22) International Filing Date:

15 March 2024 (15.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/490,968 17 March 2023 (17.03.2023) US
63/519,074 11 August 2023 (11.08.2023) US

(71) Applicant: **VENTUS THERAPEUTICS U.S., INC.**
[US/US]; 100 Beaver Street, Suite 201, Waltham, Massa-
chusetts 02453 (US).

(72) Inventors; and

(71) Applicants: **DORICH, Stéphane** [CA/CA]; 124 avenue
Pendennis, Pointe-Claire, Québec H9R 1H6 (CA). **BEV-
ERIDGE, Ramsay E.** [CA/CA]; 73 Avenue Summerhill,
Pointe-Claire, Québec H9R 2L3 (CA). **CIBLAT, Stéphane**
[CA/CA]; 1260 rue Pauline-Julien, Montreal, Québec H2J
0A2 (CA). **CÔTÉ, Alexandre** [CA/CA]; 753 Boul. Union,
Laval, Québec H7X 1X7 (CA). **CYR, Patrick** [CA/CA];
67 rue Benoit, Saint-Constant, Québec J5A 0B2 (CA). **ST-
ONGE, Miguel** [CA/CA]; 1173 rue des Mésanges, Saint-
Lazare, Québec J7T 2L5 (CA).

(74) Agent: **ERLACHER, Heidi A.** et al.; ATTN: IP Docketing
Department, 1299 Pennsylvania Avenue, NW, Suite 700,
Washington, District of Columbia 20004-2400 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,


DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF



(57) Abstract: The present disclosure relates to compounds of Formula (I-A); and pharmaceuti-
cally acceptable salts and tautomers thereof, wherein Ring A, Ring B, R¹, R^{2a}, R^{2b}, R³, m, n, and
p are described herein, and methods of preparation, methods of treatment and prevention, and
pharmaceutical compositions comprising same. The present disclosure further relates to the use
of the compounds of Formula (I-A), and pharmaceutically acceptable salts and tautomers thereof,
in the treatment and prevention of NLRP3-related diseases and disorders.

WO 2024/196788 A1